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OBJECTIVES We investigated the effects of the aldosterone blocker eplerenone alone and in combination
with angiotensin-converting enzyme (ACE) inhibition on ventricular remodeling in rats with
left ventricular (LV) dysfunction after extensive myocardial infarction (MI).
BACKGROUND Adding an aldosterone antagonist to ACE inhibition reduces mortality and morbidity in
heart failure.
METHODS Starting 10 days after MI, rats were treated with placebo, eplerenone (100 mg/kg/day), the
ACE inhibitor trandolapril (0.3 mg/kg/day), or a combination of both for nine weeks.
RESULTS Both monotherapies attenuated the rise in LV end-diastolic pressure (LVEDP) and LV
end-diastolic volume (LVEDV) compared with placebo, whereas combined treatment further
attenuated LVEDP and LVEDV, significantly improved LV function and reduced plasma
norepinephrine levels. The time constant of LV pressure isovolumic decay () was prolonged
in placebo MI rats, significantly shortened by eplerenone, and normalized by eplerenone/
trandolapril. Increased collagen type I gene expression and collagen content in the nonin-
farcted LV myocardium from MI placebo rats was attenuated by trandolapril, but almost
completely prevented by eplerenone and eplerenone/trandolapril. The addition of eplerenone
to ACE inhibition prevented sarcoplasmic-reticulum calcium ATPase downregulation and
the increases in LV gene expression of -MHC and atrial natriuretic factor more effectively
than either monotherapy. Furthermore, combination treatment attenuated the increase in
myocardial angiotensin II type 1 receptor expression and increased phosphorylated endothe-
lial nitric oxide synthase protein levels.
CONCLUSIONS The aldosterone blocker eplerenone improved LV remodeling in rats with LV dysfunction
after extensive MI. Combination therapy with an ACE inhibitor substantially potentiates this
effect by a complementary prevention of LV fibrosis, cardiac hypertrophy, and molecular
alterations. (J Am Coll Cardiol 2003;42:1666–73) © 2003 by the American College of
Cardiology Foundation
Left ventricular (LV) remodeling after myocardial infarction
(MI) involves myocyte hypertrophy, chamber dilation, and
increased collagen accumulation remote from the infarct
site, leading to impaired contractile function and heart
failure (1,2).
See page 1674
Aldosterone production in the heart (3,4) as well as
aldosterone plasma levels (5–7) are increased after MI and
in congestive heart failure (CHF), correlating with the
severity of disease. Moreover, despite complete vascular
angiotensin-converting enzyme (ACE) inhibition, plasma
aldosterone levels are elevated in CHF patients, suggesting
angiotensin II-independent aldosterone production (8). Al-
dosterone may contribute to the progression of ventricular
remodeling by promoting sodium and water retention,
sympathoadrenergic activation, endothelial dysfunction, and
vascular and myocardial fibrosis (9–13).
Aldosterone receptor blockade (for four weeks, started
early [14] or seven days [3] after MI) reduced fibrosis in the
viable myocardium of rats with moderate MI. Moreover,
long-term monotherapy with eplerenone, a novel aldoste-
rone blocker, prevented progressive LV dysfunction and
remodeling in dogs with moderate heart failure (15). The
Randomized Aldactone Evaluation Study (RALES)
showed that the aldosterone receptor antagonist spironolac-
tone added to ACE inhibition reduces morbidity and
mortality among patients with severe heart failure (16). Post
hoc substudies of the RALES and subsequent smaller trials
in postinfarction patients reported a decrease in serum
markers for cardiac collagen synthesis and a reduction of LV
dilation (17–19). However, the role of aldosterone in
addition to ACE inhibition in the pathophysiology of
postinfarction ventricular remodeling is still uncertain.
In the present study, we investigated the effects of
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long-term (nine weeks) aldosterone receptor blockade with
eplerenone alone and in combination with ACE inhibition
on hemodynamics, neurohormonal activation, and LV re-
modeling (dilation, biochemical and molecular alterations)
in rats with LV dysfunction after extensive MI.
METHODS
All procedures conformed to the guiding principles of the
American Physiological Society and were approved by the
institutional Animal Research Committee.
MI and study protocols. Left coronary artery ligations
were performed in adult male Wistar rats (200 to 250 g) (7).
Briefly, under ether anesthesia, the thorax was opened, the
heart exteriorized, and a ligature was placed around the
proximal left coronary artery. The heart was returned to its
normal position, and the thorax was closed. Mortality was
46% within the first 24 h. Sham-operated control rats
underwent the same surgical procedure except that the
suture around the coronary artery was not tied. Starting on
the tenth postoperative day, sham-operated animals re-
ceived placebo treatment, and surviving MI rats were
randomly allocated to one of the following four treatment
groups: placebo, the aldosterone blocker eplerenone, the
ACE inhibitor trandolapril, or a combination of eplerenone
and trandolapril for nine weeks. Eplerenone was given in
food, and trandolapril was administered by gavage once
daily. The dose of eplerenone (100 mg/kg/day) was selected
from previous studies in which eplerenone provided marked
end-organ protective effects in the heart and kidney of
hypertensive rats (20). Trandolapril was used at a dose of 0.3
mg/kg/day, which is the most commonly used dose for this
drug in rats with heart failure (7,11).
Hemodynamic and LV volume measurements. Left ven-
tricular systolic pressure, LV end-diastolic pressure
(LVEDP), mean arterial pressure, maximal rate of pressure
rise and decline (dP/dtmax and dP/dtmin, respectively), and
heart rate were measured 10 weeks after MI, under pento-
barbital anesthesia (30 mg/kg body weight, intraperitone-
ally). Saline-filled catheters (polyethylene-50) were ad-
vanced from the right carotid artery into the LV and
connected via a three-way stopcock to a Millar microma-
nometer and Statham transducer. The time constant of LV
pressure isovolumic decay (regression of log [pressure] vs.
time) was calculated by the Weiss method (21). Correlation
coefficients for all studies were 0.99. The in vivo LV
pressure-volume relationship was analyzed using a conduc-
tance catheter (SPR-774, Millar Instruments, Houston,
Texas). The 1.4 F catheter was advanced from the right
carotid artery into the LV through the polyethylene-50,
saline-filled catheter after hemodynamic measurements.
Pressure-volume signals were acquired by BioBench soft-
ware (National Instruments, Austin, Texas). Pvan software
(Millar Instruments) was used to analyze all pressure-
volume loop data recorded at steady-state and during
injection of hypertonic saline for the calibration of parallel
conductance volume (22). The LV volume was calculated
for each rat from conductance volume corrected by the
relative parallel conductance volume.
Sample collection, infarct size. The right ventricle (RV)
and the LV, including septum, were separated in ice-cold
saline and weighed. Infarct size was quantified histologically
by planimetry. The LV was cut into three transverse
sections: apex, middle ring (3 mm), and base. From the
middle ring, 5-m sections were cut at 100-m intervals
and stained with picrosirius red. Infarct size (fraction of the
infarcted LV) was calculated as the average of all slices and
expressed as a percentage of length. Only rats with extensive
infarcts (45%) were included in the study.
Neurohormonal assay. After hemodynamic measurement,
a blood sample was collected from the right carotid artery.
Plasma norepinephrine was measured with high-
performance liquid chromatography, and N-terminal pro-
atrial natriuretic peptide (NT-proANP) was measured by
radioimmunoassay (Immunodiagnostik, Bensheim, Germany).
Quantification of cardiac gene expression. Total ribo-
nucleic acid was isolated from LV samples (noninfarcted
LV myocardium) using TRIzol reagent (Invitrogen,
Karlsruhe, Germany). Atrial natriuretic factor (ANF), collagen
1(I), and glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) gene expression were determined by competitive
polymerase chain reaction (PCR) as described (7). Heter-
ologous internal standards were constructed with a Com-
petitive DNA PCR Kit (TaKaRa, Shiga, Japan). Products
of PCR amplification were separated on 2% agarose gel. A
given messenger ribonucleic acid (mRNA) level was ex-
pressed as a ratio with respect to the level of mRNA for
GAPDH. - and -myosin heavy chain (MHC) mRNA
was amplified by PCR as previously described (7). After
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANF  atrial natriuretic factor
ANOVA  analysis of variance
AT1  angiotensin II type 1
CHF  congestive heart failure
dP/dtmax  maximal rate of pressure rise
dP/dtmin  maximal rate of pressure decline
eNOS  endothelial nitric oxide synthase
GAPDH  glyceraldehyde-3-phosphate-
dehydrogenase
LV  left ventricle/ventricular
LVEDP  left ventricular end-diastolic pressure
LVEDV  left ventricular end-diastolic volume
MHC  myosin heavy chain
MI  myocardial infarction
MMP  matrix metalloproteinase
mRNA  messenger ribonucleic acid
NT-proANP  N-terminal pro-atrial natriuretic peptide
PCR  polymerase chain reaction
RALES  Randomized Aldactone Evaluation Study
RV  right ventricle/ventricular
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digestion with the restriction enzyme Tru9I, fragments of
the PCR amplification product were separated on 8%
polyacrylamide gel.
Myocardial hydroxyproline. For hydroxyproline determi-
nation, LV samples (noninfarcted LV myocardium) were
freeze-dried, weighed, and hydrolyzed in 6N HCl at 110°C
for 24 h. Hydroxyproline concentration was measured
spectrophotometrically, and collagen content was expressed
in g/mg dry tissue weight assuming that collagen contains
an average of 13.4% in hydroxyproline (7).
Western blot analysis. The LV samples (noninfarcted LV
myocardium) were homogenized in ice-cold RIPA buffer
(150 mmol/l NaCl, 50 mmol/l Tris-Cl, 5 mmol/l ethyl-
enediaminetetraacetic acid, 1% v/v Nonidet P-40, 0.5% w/v
deoxycholate, 10 mmol/l NaF, 10 mmol/l sodium pyro-
phosphate, 100 mmol/l phenylmethylsulfonyl fluoride, 2
g/ml aprotinin, and 2 g/ml leopeptin). Proteins were
determined by Bradford assay. Myocardial extracts (30 g
protein per lane) were mixed with sample loading buffer and
under reducing conditions separated on 10% sodium dode-
cyl sulfate-polyacrylamide gel. Proteins were electrotrans-
ferred overnight at 4°C onto polyvinylidene difluoride
membrane (Immun-Blot, Bio-Rad, Mu¨nchen, Germany).
The bands were detected using chemiluminescence assay
(ECLPlus, Amersham, Freiburg, Germany). Primary an-
tibodies used recognize the following: matrix metallopro-
teinase 13 (MMP-13) (MAB-13426, Chemicon Interna-
tional, Hofheim, Germany); angiotensin II type 1 (AT1)
receptor (sc-579, Santa Cruz Biotechnology, Heidelberg,
Germany); sarcoplasmic-reticulum calcium adenosine
triphosphatase (SERCA2 ATPase; MA3-919, Affinity
BioReagents, Alexis Biochemicals, Grunberg, Germany);
endothelial nitric oxide synthase (eNOS) (N-30020, Trans-
duction Laboratories, BD Biosciences, Heidelberg, Ger-
many); and phosphorylated eNOS at Ser1177 (9571, Cell
Signaling Technology, Frankfurt, Germany).
Statistical analysis. The main effects of the drug were
tested by two-factor analysis of variance (ANOVA) for
repeated measures, and differences between the groups were
assessed by one-factor ANOVA with post hoc comparisons
by the Fisher protected least significant difference test.
Statistical analysis was performed using the SuperANOVA
statistic program (Abacus Concepts, California). Statistical
significance was assumed at p  0.05. Relationships be-
tween two variables were tested by linear regression analysis.
RESULTS
Global parameters. Infarct size and body weight were
similar among the experimental groups (Table 1). The LV
weight and LV weight/body weight were reduced in the
eplerenone/trandolapril-treated MI group compared with
placebo. The RV weight and RV weight/body weight were
markedly higher in placebo-treated MI rats compared with
sham-operated control rats and were significantly reduced
by both monotherapies. Combination therapy led to a
significant further decrease in RV compared with mono-
therapy with either eplerenone or trandolapril (Table 1).
Hemodynamics and LV remodeling. Mean arterial pres-
sure and LV systolic pressure were reduced in all MI groups
irrespective of treatment (Table 1). The MI rats on placebo
developed elevated LVEDP and a markedly lower dP/dtmax
and dP/dtmin. Monotherapy with eplerenone or trandolapril
attenuated LVEDP and tended to enhance dP/dtmax and
dP/dtmin, whereas combined treatment further prevented
the rise in LVEDP and significantly improved dP/dt (Table
1). The time constant of LV pressure isovolumic decay ()
was prolonged in placebo MI rats, attenuated by trandola-
pril, significantly shortened by eplerenone, and normalized
by eplerenone/trandolapril (Fig. 1A). Myocardial infarction
resulted in a rightward shift of the LV pressure-volume
loops to high volumes (Fig. 1B). Eplerenone and trandola-
Table 1. Global Parameters of Sham-Operated Rats (Sham) and Rats With LV Dysfunction 10 Weeks After MI: Effects of










MI (n  21)
Infarct size (%) — 53.3  0.9 55.2  1.4 55.2  1.3 54.3  1.4
BW (g) 451  9 448  10 440  20 433  11 426  12
LV (g) 0.83  0.02 0.81  0.03 0.77  0.04 0.76  0.02 0.69  0.03*†
LV/BW (mg/g) 1.84  0.04 1.81  0.05 1.78  0.1 1.74  0.05 1.64  0.06*‡
RV (g) 0.23  0.01 0.49  0.02* 0.40  0.03*† 0.39  0.02*† 0.30  0.02*§
RV/BW (mg/g) 0.50  0.02 1.11  0.02* 0.94  0.08*‡ 0.92  0.04*† 0.74  0.05*§
MAP (mm Hg) 124  3 95  3* 106  3* 96  7* 103  3*
LVSP (mm Hg) 136  3 112  3* 112  4* 109  3* 110  2*
LVEDP (mm Hg) 4.3  0.5 21.7  2* 14.8  3*‡ 15.9  3*‡ 11.6  2*§
dP/dtmax (mm Hg/s) 11,845  335 7,688  237* 8479  477* 8,453  288* 8,901  267*†
dP/dtmin (mm Hg/s) 8,855  424 4,841  165* 5477  305* 5,278  254* 5,521  166*‡
Heart rate (beats/min) 400  9 353  9* 358  7* 363  11* 376  12
NT-proANP (nmol/l) 0.71  0.14 3.19  0.48* 2.47  0.26* 2.31  0.24*‡ 1.43  0.23§
Norepinephrine (pg/ml) 213  25 469  71* 305  57 312  60 217  19†
Values are mean  SEM. *p  0.05 versus Sham. †p  0.01, ‡p  0.05, §p  0.001 versus placebo MI. p  0.05 versus eplerenone MI and trandolapril MI.
ACE  angiotensin-converting enzyme; BW  body weight; dP/dtmax  maximal rate of pressure rise; dP/dtmin  maximal rate of pressure decline; LV  left ventricular;
LVEDP  left ventricular end-diastolic pressure; LVSP  left ventricular systolic pressure; MAP  mean arterial pressure; MI  myocardial infarction; NT-proANP 
N-terminal pro–atrial natriuretic peptide.
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pril prevented the rightward shift of LV volume and
significantly attenuated the LV end-diastolic volume
(LVEDV) compared with placebo. However, combination
therapy led to a substantial further leftward shift of the LV
pressure-volume curve and a decrease in LVEDV compared
with monotherapies. The LV ejection fraction was lower in
placebo MI rats compared with control rats (30 2% vs. 69
 4%, p  0.001) and was significantly improved only in
the eplerenone/trandolapril-treated MI group (42  3%, p
 0.01).
NT-proANP and norepinephrine. Myocardial infarction
was characterized by a marked increase in circulating NT-
proANP and norepinephrine levels (Table 1). The NT-
proANP levels tended to be reduced by eplerenone (p 
0.11) and were significantly decreased by trandolapril. How-
ever, combination therapy significantly further attenuated
plasma NT-proANP concentrations compared with mono-
therapies. The increase in plasma norepinephrine levels was
attenuated by eplerenone (p  0.06) and trandolapril (p 
0.06) monotherapy and significantly reduced by eplerenone/
trandolapril treatment.
LV fetal gene expression. The ratio of LV -MHC to
-MHC mRNA and ANF gene expression, molecular
markers of hypertrophy, were substantially increased in
placebo MI rats and attenuated by trandolapril and, to a
lesser degree, by eplerenone monotherapy. Eplerenone/
trandolapril treatment led to an additional attenuation of
cardiac -MHC and ANF mRNAs (Fig. 2).
LV fibrosis. The LV collagen concentrations were in-
creased in placebo MI rats, attenuated by trandolapril, and
nearly normalized by eplerenone and eplerenone/
trandolapril (Fig. 3). The rise in collagen type I gene
expression in the noninfarcted LV myocardium from MI
placebo rats was attenuated by trandolapril but almost
completely prevented by eplerenone and eplerenone/
trandolapril. Collagen type I mRNA levels significantly
correlated with dP/dtmax (r  0.52, p  0.01), dP/dtmin (r
 0.52, p  0.01), and  (r  0.82, p  0.01). Left
ventricular MMP-13 (59 kDa) protein expression was
increased in placebo MI rats compared with control rats.
This increase was attenuated by eplerenone and trandolapril
and further inhibited by eplerenone/trandolapril.
Figure 1. (A) The time constant of left ventricular pressure decay (Tau), and (B) left ventricular (LV) pressure–volume (P-V) loops and left ventricular
end-diastolic volume measured in vivo with conductance catheter in sham-operated rats (Sham) and in rats with extensive myocardial infarction (P MI):
Effects of aldosterone receptor inhibition (E), ACE inhibition (T), or combined aldosterone and ACE inhibition (ET). Mean  SEM (n  6 to 12).
*p  0.05 versus Sham; ‡p  0.05, †p  0.001, ††p  0.0001 versus P MI; #p  0.05 versus E MI; **p  0.059 versus T MI.
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AT1 receptor, SERCA2 ATPase, eNOS protein. The
increase in AT1 receptor protein expression in the nonin-
farcted LV from placebo MI rats tended to be attenuated by
eplerenone and trandolapril monotherapy; however, it was
significantly prevented only by combination therapy (Fig.
4). The SERCA2 ATPase downregulation in placebo MI
rats was attenuated by trandolapril and completely pre-
vented by eplerenone/trandolapril. The SERCA2 ATPase
protein expression significantly correlated with dP/dtmax
(r  0.45, p  0.01), dP/dtmin (r  0.45, p  0.01), and 
(r 0.60, p 0.01). There was no difference in total eNOS
protein expression among the groups studied (data not
shown). In contrast, treatment with eplerenone/trandolapril
resulted in a significant eNOS phosphorylation at Ser1176 in
MI rats (Fig. 4).
DISCUSSION
Our study shows improvement of LV remodeling by long-
term aldosterone receptor antagonism in rats with severe LV
dysfunction after extensive MI. We suppose that the favor-
able effects of eplerenone were likely mediated in part by the
reduction of LV fibrosis in the remote noninfarcted myo-
cardium, a major determinant of ventricular remodeling in
ischemic cardiomyopathy (2). Alterations in the collagen
matrix impair myocyte relengthening, leading to relaxation
abnormalities, progressive diastolic dysfunction, and heart
failure (2,13). In patients with hypertensive heart disease,
regression of myocardial fibrosis was associated with im-
provement of LV relaxation (23). In dogs with moderate
heart failure, Suzuki et al. recently reported that eplerenone
reduced interstitial fibrosis and improved ventricular func-
Figure 2. Ratios of messenger ribonucleic acid expression -myosin heavy chain (MHC) to -MHC and of atrial natriuretic factor (ANF) to
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) in the left ventricle of sham-operated rats (Sham) and in the noninfarcted left ventricular
myocardium of rats with extensive myocardial infarction (P MI): Effects of aldosterone receptor inhibition (E), ACE inhibition (T), or combined
aldosterone and ACE inhibition (ET). Mean  SEM (n  5 to 7). *p  0.05 versus Sham; ‡p  0.05, †p  0.005, ††p  0.0001 versus P MI; #p 
0.05 versus E MI.
Figure 3. Type I collagen messenger ribonucleic acid levels, collagen concentration, and matrix metalloproteinase (MMP)-13 protein expression in the left
ventricle of sham-operated rats (Sham) and in the noninfarcted left ventricular myocardium of rats with extensive myocardial infarction (P MI): Effects of
aldosterone receptor inhibition (E), ACE inhibition (T), or combined aldosterone and ACE inhibition (ET). Mean  SEM (n  5 to 11). *p  0.05
versus Sham; ‡p  0.05, †p  0.01, ††p  0.001 versus P MI. GAPDH  glyceraldehyde-3-phosphate-dehydrogenase.
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tion (15). Thus, the beneficial effects on isovolumetric
relaxation by eplerenone might partly be due to the preven-
tion of collagen deposition in the remote LV myocardium.
Limitation of the aldosterone-related excessive collagen
synthesis may be one of the various extrarenal mechanisms
contributing to the clinical benefit of spironolactone in the
RALES trial (17). In fact, serum markers for cardiac
collagen synthesis were associated with poor outcome in
CHF patients and were decreased by spironolactone ther-
apy. Moreover, the reduction of MMP-13 could account for
the improvement of LV remodeling. Indeed, upregulation
of MMPs results in increased deposition of poorly struc-
tured fibrotic tissue in the myocardium and contributes to
the development of progressive ventricular dilation and
failure (24). Locally produced or circulating aldosterone
stimulates cardiac fibrosis either directly via mineralocorti-
coid receptors or indirectly by interfering with AT1 recep-
tors (13,25). In addition, involvement of other factors has
been implicated in aldosterone-induced myocardial fibrosis
such as endothelin (26), bradykinin (27), and calcium (28).
Reduction of LV AT1 receptor expression by eplerenone
may contribute to decreased cardiac fibrosis, similar to
observations in aldosterone-salt-treated rats, where spirono-
lactone attenuated the upregulation of cardiac AT1 receptor
(25).
The beneficial effects of long-term eplerenone treatment
on LV remodeling were probably also related to the pre-
vention of pathologic hypertrophy, as shown by the reduc-
tion of fetal genes such as -MHC and ANF. Recent
evidence that targeted overexpression of human mineralo-
corticoid receptor resulted in dilated cardiomyopathy and
increased cardiac ANF expression supports our hypothesis
(29). Experimental animal data suggest a role for aldoste-
rone in mediating cardiac hypertrophy. Aldosterone recep-
tor blockade attenuated cardiac hypertrophy in dogs with
CHF (15) and in stroke-prone spontaneously hypertensive
rats (30). In rats harboring the human renin and angio-
tensinogen genes, aldosterone antagonism, like AT1 recep-
tor inhibition, reduced cardiac hypertrophy and fibrosis,
suggesting that angiotensin II-induced end-organ damage
might arise via aldosterone-related mechanisms (31). How-
ever, the mechanisms underlying aldosterone-induced car-
diac hypertrophy are not completely understood. Increased
AT1 receptor expression as well as calcineurin activity
caused by aldosterone may play a role (32).
Additive effects of combination therapy with ACE inhib-
itor and eplerenone. Several studies have shown that
monotherapy with ACE inhibitors after MI improved LV
loading conditions, remodeling, and neurohormonal activa-
tion, as confirmed in the present study (33). However, ACE
inhibition combined with aldosterone antagonism provided
additional beneficial effects on LV hemodynamics and
remodeling. This may be related to the observation of
complementary effects on LV fibrosis and hypertrophy of
the respective monotherapies: Although eplerenone was
superior to ACE inhibition in reducing LV fibrosis, ACE
inhibition had a greater effect on fetal gene expression and
SERCA2 ATPase protein levels. Therefore, aldosterone
receptor and ACE inhibition might be a particularly favor-
able combination regarding their action profile.
Combination therapy improved LV contractile function
and both the load-dependent (dP/dtmin) and load-
independent () indices of LV relaxation (34,35). Because
SERCA2 ATPase downregulation in hypertrophied and/or
failing myocardium is linked to systolic and diastolic dys-
function (36), the improved cardiac function by combined
therapy might partly be due to prevention of SERCA2
ATPase downregulation. In rats with heart failure,
SERCA2 ATPase gene transfer improved not only contrac-
tile function but also survival, cardiac energetics, and re-
modeling (37), suggesting that impaired SERCA2 ATPase
function represents a key mechanism linking deleterious
Figure 4. Protein expression of angiotensin II type 1 (AT1) receptor, sarcoplasmic-reticulum calcium (SERCA2) ATPase, and phosphorylated endothelial
nitric oxide synthase (eNOS) in the left ventricle of sham-operated rats (Sham) and in the noninfarcted left ventricular myocardium of rats with extensive
myocardial infarction (P MI): Effects of aldosterone receptor inhibition (E), ACE inhibition (T), or combined aldosterone and ACE inhibition (ET).
Mean  SEM (n  7 to 11). *p  0.05 versus Sham; ‡p  0.05, †p  0.005 versus P MI.
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effects of the upregulated renin-angiotensin-aldosterone
system post MI to contractile dysfunction, hypertrophy, and
heart failure. Moreover, the favorable functional effects of
beta-blockers in CHF patients are related to SERCA
ATPase upregulation (38).
Combination therapy particularly increased myocardial
phosphorylated eNOS protein levels. Phosphorylation of
eNOS activates the enzyme leading to nitric oxide produc-
tion (39). The pivotal role of eNOS for LV remodeling after
MI was recently demonstrated in eNOS knockout mice that
exhibited excessive LV dysfunction, hypertrophy, and dila-
tion (40). Furthermore, in these mice, the beneficial effects
of ACE inhibitor and AT1 antagonist therapy on LV
remodeling were substantially attenuated (41), suggesting
that an increase in cardiac eNOS activity contributes to the
cardioprotective effects of various established pharmacologic
interventions. The addition of spironolactone to ACE
inhibitor therapy in rats with heart failure after MI partic-
ularly increased the bioavailability of endothelium-derived
nitric oxide associated with reduced superoxide anion for-
mation (11). The impact of oxidative stress on LV remod-
eling after MI has been convincingly demonstrated in recent
studies (42). As eplerenone reduces superoxide formation
(43), a beneficial shift in the balance of nitric oxide and
superoxide may have improved cardiac performance and
remodeling.
The reduction in plasma norepinephrine may have con-
tributed to more benefit of combination therapy by prevent-
ing the adverse cardiovascular effects of excessive sympa-
thetic stimulation. Because in post-MI rats the ANF system
(44) is activated in relation to the increase in intracardiac
pressures, in the treated groups hemodynamic improvement
and prevention of cardiac failure likely accounted for the
reduction of atrial natriuretic peptide. Results from the
RALES neurohormonal substudy (45) and of Tsutamoto et
al. (18) also showed decreased circulating levels of natri-
uretic peptides in patients with severe CHF after spirono-
lactone treatment.
Clinical implications. Although smaller trials in postin-
farction patients and post hoc substudies of the RALES
trial reported a reduction in LV dilation and a decrease in
myocardial collagen synthesis after spironolactone therapy
(17–19), our results provide important new insights into the
potential mechanisms underlying cardioprotection by aldo-
sterone antagonism combined with ACE inhibition.
Study limitations. Similar to previous observations in pla-
cebo rats with extensive MI, arterial pressure was lowered
(42) without an additional hypotensive effect of the phar-
macologic intervention. As we did not assess changes in
systemic vascular resistance, it remains unclear from this
study whether the more favorable effects of combined
treatment were achieved in part by afterload reduction.
Furthermore, we did not evaluate the LV end-systolic
pressure-volume relationships at different loading condi-
tions. Thus, future experiments should elucidate the effects
of eplerenone and eplerenone/trandolapril on the inotropic
state under acutely changing conditions independent of
end-diastolic volume and the systolic pressure. Finally, the
employed post hoc Fisher protected least significant differ-
ence test is limited to exert a real control for multiple
comparisons.
In summary, aldosterone receptor blockade with
eplerenone improved LV remodeling in rats with LV
dysfunction after extensive MI. Combination therapy with
an ACE inhibitor substantially potentiated this effect.
Complementary prevention of neurohormonal activation,
cardiac fibrosis, and cardiac hypertrophy appear to contrib-
ute to these beneficial effects.
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